OVID
Price
$2.78Alerts
Change
-$0.02 (-0.71%)
Updated
Nov 11 closing price
Capitalization
556.6M
123 days until earnings call
Intraday BUY SELL Signals
TLX
Price
$9.72Alerts
Change
+$0.28 (+2.96%)
Updated
Nov 11 closing price
Capitalization
3.27B
Intraday BUY SELL Signals
Interact to see
Advertisement

OVID vs TLX

OVID vs TLX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
OVID vs. TLX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OVID is a Buy and TLX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for OVID with price predictions
Nov 11, 2026

OVID's RSI Oscillator ascending out of oversold territory

The RSI Indicator for OVID moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 23 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on OVID as a result. In 80 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for OVID just turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 46 of 52 cases over the following month. The odds of a continued upward trend are 88%.

OVID moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for OVID crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +14.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 158 of 189 cases where OVID Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 57 cases where OVID's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

OVID broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (3.498). P/E Ratio (-13.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for TLX with price predictions
Nov 11, 2026

TLX's Stochastic Oscillator stays in overbought zone for 3 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

The Aroon Indicator for TLX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLX's RSI Oscillator exited the oversold zone, 8 of 11 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TLX as a result. In 17 of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

The Moving Average Convergence Divergence (MACD) for TLX just turned positive on November 05, 2026. Looking at past instances where TLX's MACD turned positive, the stock continued to rise in 13 of 17 cases over the following month. The odds of a continued upward trend are 76%.

Following a +4.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLX advanced for three days, in 79 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

TLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. TLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.710) is normal, around the industry mean (3.498). TLX has a moderately high P/E Ratio (97.568) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.354) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
OVID: Fundamental Ratings
OVID
OUTLOOK RATING
1..100
39
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
76
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
OVIDTLX
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
61%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 9 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
77%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (OVID: $2.78 vs. TLX: $9.73)
Brand notoriety: OVID and TLX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OVID: 104% vs. TLX: 66%
Market capitalization -- OVID: $556.6M vs. TLX: $3.27B
OVID [@Biotechnology] is valued at $556.6M. TLX’s [@Biotechnology] market capitalization is $3.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OVID’s FA Score shows that 1 FA rating(s) are green while TLX’s FA Score has 0 green FA rating(s).

  • OVID’s FA Score: 1 green, 4 red.
  • TLX’s FA Score: 0 green, 5 red.
According to our system of comparison, OVID is a better buy in the long-term than TLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OVID’s TA Score shows that 7 TA indicator(s) are bullish while TLX’s TA Score has 5 bullish TA indicator(s).

  • OVID’s TA Score: 7 bullish, 3 bearish.
  • TLX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, OVID is a better buy in the short-term than TLX.

Price Growth

OVID (@Biotechnology) experienced а +1.46% price change this week, while TLX (@Biotechnology) price change was +0.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

OVID is expected to report earnings on Mar 15, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been loosely correlated with CLDX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-0.71%
CLDX - OVID
42%
Loosely correlated
-1.63%
SLDB - OVID
42%
Loosely correlated
+6.00%
VIR - OVID
41%
Loosely correlated
-0.15%
SANA - OVID
40%
Loosely correlated
-5.76%
DNTH - OVID
40%
Loosely correlated
+0.55%
More

TLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLX has been loosely correlated with GNPX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if TLX jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLX
1D Price
Change %
TLX100%
+2.91%
GNPX - TLX
35%
Loosely correlated
+9.57%
APVO - TLX
32%
Poorly correlated
-29.63%
SLDB - TLX
29%
Poorly correlated
+6.00%
PRME - TLX
28%
Poorly correlated
+10.26%
OVID - TLX
27%
Poorly correlated
-0.71%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLNG3.910.10
+2.62%
Stabilis Solutions
FWDI5.360.12
+2.29%
Forward Industries Inc.
DV13.57N/A
N/A
DoubleVerify Holdings
KPTI0.02N/A
N/A
Karyopharm Therapeutics Inc.
PNR69.33-0.30
-0.43%
Pentair plc